InvestorsHub Logo
Followers 399
Posts 86391
Boards Moderated 2
Alias Born 02/05/2004

Re: None

Tuesday, 05/21/2019 8:24:50 AM

Tuesday, May 21, 2019 8:24:50 AM

Post# of 641483
Adma Biologics Inc (ADMA) President and CEO Adam S Grossman Bought $120,000 of Shares
May 21, 2019 | About: ADMA +0%
GuruFocus has detected 2 Warning Signs with ADMA Biologics Inc adma.
Piotroski F-Score: Low
Revenue per Share: Declined
President and CEO of Adma Biologics Inc (NASDAQ:ADMA) Adam S Grossman bought 30,000 shares of ADMA on 05/17/2019 at an average price of $4 a share. The total cost of this purchase was $120,000.

ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases. ADMA Biologics Inc has a market cap of $193.870 million; its shares were traded at around $4.18 with and P/S ratio of 11.50. ADMA Biologics Inc had annual average EBITDA growth of 8.50% over the past five years.

CEO Recent Trades:

President and CEO Adam S Grossman bought 30,000 shares of ADMA stock on 05/17/2019 at the average price of $4. The price of the stock has increased by 4.5% since.
Warning! GuruFocus has detected 2 Warning Signs with ADMA. Click here to check it out.
ADMA 30-Year Financial Data
The intrinsic value of ADMA
Peter Lynch Chart of ADMA
CFO Recent Trades:

EVP, CFO Brian Lenz bought 5,000 shares of ADMA stock on 05/17/2019 at the average price of $4. The price of the stock has increased by 4.5% since.
Directors and Officers Recent Trades:

Director Jerrold B Grossman bought 12,000 shares of ADMA stock on 05/17/2019 at the average price of $4. The price of the stock has increased by 4.5% since.
Director Lawrence P. Guiheen bought 25,000 shares of ADMA stock on 05/17/2019 at the average price of $4. The price of the stock has increased by 4.5% since.
EVP, CSO and CMO James Mond bought 4,500 shares of ADMA stock on 05/17/2019 at the average price of $4. The price of the stock has increased by 4.5% since.




That is a great sign when insiders are buying up their own offerings. I am sure they were very happy with the two FDA approvals they just got.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.